Obesity control prior to infertility therapy is still difficult. To date, no evidence of an increased live birth rate has been found in randomised clinical trials addressing weight loss through lifestyle treatments. The purpose of this study was to see if pharmacologic weight-loss intervention prior to in vitro fertilisation and embryo transfer might increase the live birth rate in overweight or obese women. From July 2017 to January 2019, the study performed a randomised, double-blind, placebo-controlled study at 19 Chinese reproductive medical facilities. A total of 877 infertile women with a BMI of 25 or above who were scheduled for IVF were randomly allocated to either orlistat or placebo therapy for 4 to 12 weeks. The primary outcome metric was the live birth rate following fresh ET. The live birth rate did not differ substantially between the two groups. There were no significant differences in the rates of conception, clinical pregnancy, or pregnancy loss across the groups. After orlistat therapy, there was a statistically significant rise in singleton birth weight. The orlistat group’s mean change in body weight during the intervention was 2.49 kg, compared to 1.22 kg in the placebo group.

Although it was effective for weight loss, orlistat therapy prior to IVF-ET did not increase the live birth rate among overweight or obese women.